Based on pioneering work by Huggins, Hodges and others, hormonal therapies have been
established as an effective approach for advanced prostate cancer (PC) for the past eight …

Purpose: ZEN-3694 is a bromodomain extraterminal inhibitor (BETi) with activity in
androgen-signaling inhibitor (ASI)-resistant models. The safety and efficacy of ZEN-3694 …

Prostate cancer (PCa) is a malignant epithelial tumor of the prostate gland with a high male
cancer incidence. Numerous studies indicate that abnormal function of ubiquitin …

Purpose: Sabizabulin, an oral cytoskeleton disruptor, was tested in a phase Ib/II clinical
study in men with metastatic castration-resistant prostate cancer (mCRPC). Patients and …

Purpose: Enzalutamide is a second-generation androgen receptor (AR) inhibitor that has
improved overall survival (OS) in metastatic castration-resistant prostate cancer (CRPC) …

Snake venoms consist of a complex mixture of many bioactive molecules. Among them are
disintegrins, which are peptides without enzymatic activity, but with high binding affinity for …

Understanding the molecular mechanisms underlying prostate cancer (PCa) progression
towards its most aggressive, castration-resistant (CRPC) stage is urgently needed to …

Background and objective Innovations have improved outcomes in advanced prostate
cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that …

Objective: This study aimed to evaluate the survival outcomes of patients with bladder outlet
obstruction (BOO) and metastatic prostate cancer (mPCa) after having a palliative …

Background The real-world EPIX study was conducted to gather information about the
characteristics of patients with metastatic castration-resistant prostate cancer (mCRPC) who …